U.S. Securities and
Exchange Commission 
Washington, D.C. 20549

Form 10-QSB

(Mark One)

| | [X] | QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934 For the period ended January 31, 2006
| | --- | -----------------------------------------------------------------------------------------------------------------------

| | [  ] | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [No
Fee Required] For the transition period from______ to _______
| | ---- | ----------------------------------------------------------------------------------------------------------------------------------------------------

Commission
File number 0-21019

PURE Bioscience (Name of small business
issuer in its charter)

|                                                                                         |                                  
|---------------------------------------------------------------------------------------- | ---------------------------------
|California                                                                               | 33-0530289                       
|(State or other jurisdiction of incorporation or     
                     organization) | (IRS Employer Identification No.)

1725 Gillespie Way, El
Cajon, California 92020(Address of principal
executive offices)

619 596 8600Issuers telephone
number

Check
whether the issuer (1) filed all reports to be filed by Section 13 or 15(d) of the
Exchange Act during the past 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. Yes X   No

Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act). Yes XNo

State
the number of shares outstanding of each of the issuers classes of common equity as
of the latest practicable date: 18,791,834 as of March 15, 2006.

---



Index

|                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
|------------------------------------------------------------------------------------------------------------------------------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|Part I          
                
                
                
                
                
                
Part II | Financial Information
Item 1.                       
                              
                              
                              
Item 2.                       
Item 3.                       
                     
Other Information
Item 1.                       
Item 2.                       
Item 3.                       
Item 4.                       
Item 5.                       
Item 6.                       
               
Signatures and Certifications | Financial Statements
Balance Sheets as of July 31, 2005 and January 31, 2006
Statements of Operations for the three and six months ended January 31, 2006 and 2005
Statements of Cash Flows for the six months ended January 31, 2006 and 2005
Management's Discussion and Analysis of Financial Condition and Results of Operations
Controls and Procedures
Legal Proceedings
Changes in Securities
Defaults Upon Senior Securities: None
Submission of Matters to a Vote of Security Holders: None
Other Information
Exhibits and Reports on Form 8-K
|                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
|                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

2

---



CONSOLIDATED BALANCE
SHEETS

---

|                                                           | (Unaudited)
Jan 31
2006 |  | July 31
2005 |            
|---------------------------------------------------------- | ----------------------- |  | ------------ | -----------
|ASSETS                                                     |                         |  |              |            
|Current Assets                                             |                         | 
|Cash and cash equivalents                                  |                         |  | $            | 72,631     
|Accounts receivable, net of allowance for doubtful         |                         | 
|accounts of $ 8,000 at July 31, 2005 and                   |                         | 
|$8,000 at January 31, 2006                                 |                         |  |              | 51,257     
|Other receivables                                          |                         |  |              |           
|Notes receivable                                           |                         |  |              |           
|Inventories                                                |                         |  |              | 96,384     
|Prepaid expenses                                           |                         |  |              | 47,814     
|Interest receivable                                        |                         |  |              |           
|                                                           |                         |  |              |            
|Total current assets                                       |                         |  |              | 268,086    
|                                                           |                         |  |              |            
|Property, Plant and Equipment                              |                         | 
|Property, plant and equipment                              |                         |  |              | 126,421    
|                                                           |                         |  |              |            
|Total property, plant and equipment                        |                         |  |              | 126,421    
|                                                           |                         |  |              |            
|Other Assets                                               |                         | 
|Prepaid consulting                                         |                         |  |              | 548,508    
|Deposits                                                   |                         |  |              | 9,744      
|Patents and licenses                                       |                         |  |              | 2,116,126  
|                                                           |                         |  |              |            
|Total other assets                                         |                         |  |              | 2,674,378  
|                                                           |                         |  |              |            
|Total assets                                               |                         |  | $            | 3,068,884  
|                                                           |                         |  |              |            
|                                                           |                         | 
|LIABILITIES AND STOCKHOLDERS EQUITY                        |                         | 
|Current Liabilities                                        |                         | 
|Accounts payable                                           |                         |  | $            | 131,458    
|Accrued liabilities                                        |                         |  |              | 242,712    
|Income taxes payable                                       |                         |  |              |           
|                                                           |                         |  |              |            
|Total current liabilities                                  |                         |  |              | 374,170    
|                                                           |                         |  |              |            
|Stockholders' Equity                                       |                         | 
|Preferred Stock                                            |                         |  |              |           
|Class A common stock, no par value:                        |                         | 
|50,000,000 shares authorized                               |                         | 
|18,378,305 issued and outstanding at January 31, 2006, and |                         | 
|17,713,306 issued and outstanding at July 31, 2005         |                         |  |              | 20,581,497 
|Warrants:                                                  |                         | 
|622,429 issued and outstanding at January 31, 2006, and    |                         | 
|640,929 issued and outstanding at July 31, 2005            |                         |  |              | 196,643    
|Accumulated deficit                                        |                         |  |              | (18,083,426
|                                                           |                         |  |              |            
|Total stockholders' equity                                 |                         |  |              | 2,694,714  
|                                                           |                         |  |              |            
|Total liabilities and stockholders' equity                 |                         |  | $            | 3,068,884  
|                                                           |                         |  |              |            

The accompanying notes
are an integral part of these financial statements

3

---



CONSOLIDATED STATEMENTS
OF OPERATIONS

---

|                                             | For the Six Months Ended
January 31 |  | For the Three Months Ended
January 31 |           
|-------------------------------------------- | ----------------------------------- |  | ------------------------------------- | ----------
|
|Net revenues                                 |                                     |  | $                                     | 114,611   
|Cost of sales                                |                                     |  |                                       | 43,993    
|                                             |                                     |  |                                       |           
|Gross profit                                 |                                     |  |                                       | 70,619    
|                                             |                                     |  |                                       |           
|Selling expenses                             |                                     |  |                                       | 241,671   
|General and administrative expenses          |                                     |  |                                       | 866,723   
|Research and development                     |                                     |  |                                       | 483,508   
|                                             |                                     |  |                                       |           
|Total operating costs                        |                                     |  |                                       | 1,591,902 
|                                             |                                     |  |                                       |           
|Loss from operations                         |                                     |  |                                       | (1,521,283
|                                             |                                     |  |                                       |           
|Other income and (expense):                  |                                     | 
|Interest income                              |                                     |  |                                       | 1,194     
|Interest expense                             |                                     |  |                                       | (274      
|Other                                        |                                     |  |                                       | (8,327    
|                                             |                                     |  |                                       |           
|Total other income (expense)                 |                                     |  |                                       | (7,407    
|                                             |                                     |  |                                       |           
|Loss from continuing operations              |                                     |  |                                       | (1,528,690
|Discontinued operations:                     |                                     | 
|Income from discontinued operations          |                                     |  |                                       |          
|                                             |                                     |  |                                       |           
|Net loss before taxes                        |                                     |  |                                       | (1,528,690
|Income tax provision                         |                                     |  |                                       |          
|                                             |                                     |  |                                       |           
|Net loss after taxes                         |                                     |  | $                                     | (1,528,690
|                                             |                                     |  |                                       |           
|Net loss per common share, basic and diluted |                                     | 
|Continuing operations                        |                                     |  | $                                     | (0.09     
|Discontinued operations                      |                                     |  |                                       |          
|Income tax provision                         |                                     |  |                                       |          
|                                             |                                     |  |                                       |           
|Net loss                                     |                                     |  | $                                     | (0.09     
|                                             |                                     |  |                                       |           

CONSOLIDATED STATEMENTS
OF ACCUMULATED DEFICITS

---

|                             | (Unaudited)
                                                                      Year-to-Date 
                                                                         Ended  
                                                                       January 31  
                                                                          2006 |  | Year  
 Ended 
July 31
 2005 |             |   |   |             |  
|---------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | ---------------------------- | ----------- | - | - | ----------- | -
|Balance, beginning of period |                                                                                                                                                                                                                                                                                                                                                     |  | $                            | (16,554,736 | ) | $ | (16,237,666 | )
|                             |                                                                                                                                                                                                                                                                                                                                                     |  |                              |             |   |   |             |  
|Net income (loss)            |                                                                                                                                                                                                                                                                                                                                                     |  |                              | (1,528,690  | ) |   | (317,070    | )
|                             |                                                                                                                                                                                                                                                                                                                                                     |  |                              |             |   |   |             |  
|Balance, end of period       |                                                                                                                                                                                                                                                                                                                                                     |  | $;                           | (18,083,426 | ) | $ | (16,554,739 | )
|                             |                                                                                                                                                                                                                                                                                                                                                     |  |                              |             |   |   |             |  

The accompanying notes
are an integral part of these financial statements

4

---



CONSOLIDATED STATEMENTS
OF CASH FLOWS

---

|                                                           | For the Six Months Ended
January 31 | 
|---------------------------------------------------------- | ----------------------------------- | 
|
|Cash flows from operating activities:                      |                                     | 
|Net loss                                                   |                                     | 
|Adjustments to reconcile net income to net cash            |                                     | 
|provided by operating activities:                          |                                     | 
|Amortization                                               |                                     | 
|Depreciation                                               |                                     | 
|Services and interest paid for with stock and options      |                                     | 
|Pre-tax income from discontinued operations                |                                     | 
|Changes in assets and liabilities:                         |                                     | 
|(Increase) decrease in accounts receivable                 |                                     | 
|(Increase) decrease in other receivables                   |                                     | 
|(Increase) decrease in notes receivable                    |                                     | 
|(Increase) decrease in prepaid expense                     |                                     | 
|(Increase) decrease in interest receivable                 |                                     | 
|(Increase) decrease in inventory                           |                                     | 
|Increase (decrease) in accounts payable                    |                                     | 
|Increase (decrease) in accrued cash liabilities            |                                     | 
|Increase (decrease) in income tax payable                  |                                     | 
|Increase (decrease) in loans from shareholders             |                                     | 
|                                                           |                                     | 
|Net cash (used) in operating activities                    |                                     | 
|                                                           |                                     | 
|Cash flows from investing activities                       |                                     | 
|Investment in capitalized patents and licenses             |                                     | 
|Purchase of property, plant and equipment                  |                                     | 
|                                                           |                                     | 
|Net cash (used) in investing activities                    |                                     | 
|                                                           |                                     | 
|Cash flows from financing activities                       |                                     | 
|Proceeds from short-term loans                             |                                     | 
|Payment of short-term loans                                |                                     | 
|Proceeds from sale of common stock                         |                                     | 
|                                                           |                                     | 
|Net cash provided by financing activities                  |                                     | 
|                                                           |                                     | 
|Cash flows from discontinued operations:                   |                                     | 
|Cash flows from operation of Water Treatment Division      |                                     | 
|                                                           |                                     | 
|Net cash from discontinued operations                      |                                     | 
|                                                           |                                     | 
|Net increase (decrease) in cash and cash equivalents       |                                     | 
|                                                           |                                     | 
|Cash and cash equivalents at beginning of period           |                                     | 
|                                                           |                                     | 
|Cash and cash equivalents at end of period                 |                                     | 
|                                                           |                                     | 
|Supplemental disclosures of cash flow information          |                                     | 
|Cash paid for interest                                     |                                     | 
|Cash paid for taxes                                        |                                     | 
|                                                           |                                     | 
|Non-cash investing and financing activities:               |                                     | 
|Value of options issued in exchange for services - prepaid |                                     | 

The accompanying notes
are an integral part of these financial statements

5

---



# NOTES TO FINANCIAL
STATEMENTS

# Note 1.   Financial
Statements

The financial statements included
herein have been prepared by PURE Bioscience (we, us) without
audit, pursuant to the rules and regulations of the Securities and Exchange Commission.
Certain information and footnote disclosures normally included in the financial statements
prepared in accordance with generally accepted accounting principles have been condensed
or omitted as allowed by such rules and regulations, and we believe that the disclosures
are adequate to make the information presented not misleading. These financial statements
should be read in conjunction with our audited financial statements for the period ending
July 31, 2005 and their accompanying notes, as filed with the Securities and Exchange
Commission in our 10K-SB on October 31, 2005. While management believes the procedures
followed in preparing the financial statements contained in the financial statements
included in this quarterly report on Form 10Q-SB are reasonable, the accuracy of the
amounts are at least partially dependent upon facts that will exist and results that will
be accomplished by us later in the fiscal year. The results of operations for the interim
periods are not necessarily indicative of the results of operations for the full year.

We believe that the accompanying
unaudited financial statements contain all adjustments (including normal recurring
adjustments) necessary to present fairly the operations and cash flows for the periods
presented.

# Note 2. Business Segment
and Sales Concentrations

In accordance with the provisions of
SFAS No. 131, Disclosures about Segments of an Enterprise and Related Information, certain
information may be disclosed based on the way we organize financial information for making
operating decisions and assessing performance. SFAS 131 requires that we apply standards
based on a management approach, and requires segmentation based upon our internal
organization and disclosure of revenue and operating income based upon internal accounting
methods. In determining operating segments, we have reviewed the current management
structure reporting to the chief operating decision-maker (CODM) and analyzed
the reporting the CODM receives to allocate resources and measure performance.

Our business activity was
historically divided, managed and conducted in two basic business segments; the Water
Treatment division, including Commercial Water and Residential Retail products and the
Nutripure Water Dealer program; and the Bioscience division, consisting of our Silver
Dihydrogen Citrate antimicrobial and the Innovex line of pest control products. However,
in May 2005 we sold the assets of our Water Treatment Division to Maryland-based
Innovative Medical Services, LLC. In the financial statements included in this report, the
Water Treatment division is included as a Discontinued Operation in the Consolidated
Statements of Operations and Cash Flows presented for comparative purposes relating to the
periods ending January 31, 2005.

Subsequent to the sale of the Water
Treatment division, we have determined that based upon the end use of our products, the
value added processes made by us, the regulatory requirements, the customers and partners,
and the strategy required to successfully market finished products, we are operating in a
single segment.

During the six months ended January
31, 2006, 87% of sales were made to three strategic partners that are also developing
markets for our products. 54% of sales during the first six months of the current fiscal
year were made to U.S. domestic customers, and 46% were made to international customers.

# Note 3. Reclassifications

Certain reclassifications have been
made to previously reported statements to conform to our current financial statement
format.

# Note 4. Common Stock

In November 2005, we sold 39,999
shares of common stock in a private placement to an accredited investor, for $0.75 per
share (a total value of $30,000). In December 2005, we issued 25,000 shares of common
stock valued at $19,250 ($0.77 per share, based on the market price of the stock at the
time services were rendered) in exchange for regulatory and consulting services. In the
same month we issued options on 50,000 shares in exchange for investor relations and
investment banking consulting services, at an exercise price of $0.75, valued at $17,229
(based on the Black Scholes Option Pricing Model assuming no dividend yield, volatility of
82.23% and a risk-free interest rate of 4.25%). Additionally, in December 2005 we issued
options on 50,000 shares in exchange for business development consulting services, at an
exercise price of $0.80, valued at $15,426 (based on the Black Scholes Option Pricing
Model assuming no dividend yield, volatility of 82.23% and a risk-free interest rate of
4.25%).

In January 2006, we sold 500,000
shares of unregistered common stock in a private placement to an unaffiliated, accredited
investor at $0.75 per share (a total value of $375,000). In the same month, we issued
options on 300,000 shares in exchange for investor relations and investment banking
consulting services, at an exercise price of $1.00, valued at $154,390 (based on the Black
Scholes Option Pricing Model assuming no dividend yield, volatility of 82.23% and a
risk-free interest rate of 4.25%).

Also during the quarter, we agreed to
issue 2,000,000 options to a newly elected director of the Company, related to a two-year
consulting agreement for domestic and international business development, with vesting of
all options in future periods subject to performance under the consulting agreement. We
also agreed to issue 300,000 options to a second newly elected director of the Company,
related to a two-year consulting agreement for domestic and international business
development, with these options similarly vesting in future periods subject to performance
under the consulting agreement. See Note 5 for more detail on the accounting treatment of
these option agreements.

6

---



# Note 5. Prepaid
Consulting

During the quarter, we entered into a
two-year consulting agreement with Mr. Michael Sitton for domestic and international
business development, the compensation for which is a fee of $12,500 per month and an
option on two million shares of unregistered common stock, which vest over three years. We
also entered into a two-year consulting agreement with Secretary Tommy Thompson, for
domestic and international business development, the compensation for which is a fee of
$12,500 per month and an option on three hundred thousand shares of unregistered common
stock, which vest over three years. Under the option agreements, unvested options will not
be issued if the associated consulting agreements are terminated prior to their two year
term, and the Company does not have an obligation to register the underlying shares within
a specified period. Mr. Sitton and Mr. Thompson were each subsequently elected to our
Board of Directors.

During the quarter ended January 31,
2006, we recorded the value of the unvested options as a prepaid asset which will be
amortized over the life of the consulting agreements. Mr. Sittons and Secretary
Thompsons options were valued at an aggregate of $598,372 based on their weighted
average exercise prices of between $1.00 to $2.75, and the Black Scholes Option Pricing
Model assuming no dividend yield, volatility of 82.23% and a risk-free interest rate of
4.25%. This amount will be amortized over the two year life of the consulting agreements
at $24,932 per month. During the quarter ended January 31, 2006 we amortized two months of
consulting expense, or $49,864. As a result, we reported a prepaid asset of $548,508 as
Prepaid consulting on the face of the balance sheet as at January 31, 2006.

# Note 6. Subsequent Events

On February 17, 2006, we sold 500,000
shares of unregistered common stock in a private placement to Michael Sitton, a director
of the Company, at $0.90 per share. Also subsequent to the period ended January 31, 2006,
there was a net exercise of an option on 15,000 shares of common stock that resulted in
the issuance of 5,196 shares of common stock; we received $12,500 from the exercise of
25,000 options; and we received $10,000 from the exercise of a warrant to purchase 33,333
shares of common stock.

7

---



ITEM 2.   MANAGEMENTS
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis
should be read in conjunction with the audited and unaudited financial statements of PURE
Bioscience.

# 

OVERVIEWPURE Bioscience began as a provider
of pharmaceutical water purification products, however we are now developing into markets
with broader potential with new, proprietary bioscience products based upon our patented
silver ion antimicrobial technologies and patent pending boric acid based pesticide
technologies. In May 2005, we sold the assets of our Water Treatment Division to
Maryland-based Innovative Medical Services, LLC for $2,375,000. We used a portion of the
proceeds of the sale to retire substantially all debt, and the remainder to capitalize the
continuing commercialization of our current and future bioscience products.

# 

Bioscience TechnologyOur flagship bioscience technology is
an aqueous disinfectant, Silver Dihydrogen Citrate (SDC). A patented new
molecule, SDC is an electrolytically generated source of stabilized ionic silver that can
serve as the basis for a broad range of products in diverse markets. SDC liquid is
colorless, odorless, tasteless, non-caustic and formulates well with other compounds. As a
platform technology, our SDC-based antimicrobial is distinguished from competitors in the
marketplace because of its superior efficacy combined with reduced toxicity. We produce
and market pre-formulated, ready-to-use products, as well as varying strengths of SDC
concentrate as an additive or raw material for inclusion in other companies
products.

We currently have Environmental
Protection Agency (EPA) registration for our 2400-parts per million (ppm) technical grade
SDC concentrate (trade name Axenohl®) as well as for our Axen® and Axen®30
hard surface disinfectant products for commercial, industrial and consumer applications
including restaurants, homes and medical facilities. The Axen30 EPA registration includes
a 30 second kill time on standard indicator bacteria, a 24 hour residual kill on standard
indicator bacteria, a 2 minute kill time on some resistant strains of bacteria, 10 minute
kill time on fungi, 30 second kill time on HIV Type I, and 10 minute kill time on other
viruses. These claims distinguish the efficacy of Axen30 from many of the leading
commercial and consumer products currently on the market, while maintaining lower toxicity
ratings. Based on the EPA toxicity categorization of antimicrobial products that ranges
from Category I (high toxicity) down to Category IV, Axen30 is an EPA Category IV
antimicrobial for which precautionary labeling statements are normally not required. This
compares with Category II warning statements for most leading brands of disinfectant
products.

Our technology also shows promise as
a broad-spectrum antimicrobial and anti-fungal for use in human and veterinary healthcare
products. We have chosen to pursue approvals through the U.S. Food and Drug Administration
(FDA) by partnering with Therapeutics, Incorporated, which has assumed responsibility for
funding and managing the testing and regulatory process for selected potential FDA
regulated SDC-based products. Therapeutics, Incorporated is focusing on development of
SDC-based products for the treatment of bacterial, viral and fungal mediated diseases and
conditions, beginning with womens health products and acne treatment products.
Therapeutics, Incorporated expects its development work will result in multiple
Investigational New Drug (IND) filings with the US FDA.

We also market a patent-pending
pesticide technology, Triglycylboride which, like SDC, provides effective results
without human toxicity and is an alternative to traditional poisons. Triglycylboride has
been formulated into EPA registered RoachX® and AntX, the key products in our
Innovex® line of pest control products. In addition, the Innovex® line features
our EPA-exempt non-toxic TrapX® rodent lure, and our EPA registered CleanKill,
the SDC-based hard surface disinfectant for the pest control industry. The pest control
products are being marketed to both commercial pest control and consumer products
companies.

RESULTS OF OPERATIONS FOR THE
THREE MONTHS ENDED JANUARY 31, 2006 VERSUS THREE MONTHS ENDED JANUARY 31, 2005In May
2005 we sold the assets of our Water Treatment Division and are now completely focused on
the development of our bioscience technologies. In the financial statements included in
this Report on Form 10Q-SB, the Water Treatment division is included as a Discontinued
Operation in the Consolidated Statements of Operations and Cash Flows presented for
comparative purposes relating to the periods ending January 31, 2005.

We are at an early stage in the
development and marketing of our bioscience technologies in highly competitive markets,
and we anticipate that market acceptance of our novel technology may be a long term
achievement. Even when our SDC products have been approved by regulatory authorities and
are available for commercial sale, there is often an extended period of time in which
potential users formulate and test them before committing to significant purchases. Each
formulation of our products requires regulatory approval for each respective jurisdiction
in which it is sold, and in addition to competitive challenges, we believe that the
investment necessary to pursue research, testing and regulatory approval for SDC-based
products will continue to be significant. However, we believe we are in a position to
accelerate additional regulatory approvals and negotiate distribution, development and
marketing agreements for the inclusion of SDC into multiple global products. For example,
during the quarter ended January 31, 2006, we announced that we had entered into a supply
and distribution agreement with Enviroguard Sciences LLC, initially for the supply and
distribution of our hard surface disinfectant. As a result of this and other agreements,
we expect sales of our SDC-based products and, to a lesser extent, our pesticide products,
to accelerate in future periods.

During the quarter ended January 31,
2006, revenues of $59,400 increased by 17% over the quarter ended January 31, 2005. Gross
profit for the quarter ended January 31, 2006 was $30,300 versus $36,900 in the same
quarter of the prior fiscal year. The gross margin percentage declined from 72% to 51%
over the same period, primarily as we are now absorbing the overhead costs of our
manufacturing facility over a smaller number of products. During the quarter ended January
31, 2005, we absorbed such costs over the products of the Water Treatment Division in
addition to our bioscience products.

8

---



Operating costs increased from
$799,539 in the quarter ended January 31, 2005, to $949,579 in the quarter ended January
31, 2006. Included in these totals, selling expenses declined by $57,609, to $143,856 in
the current quarter compared with the same quarter in the prior fiscal year, primarily due
to consulting expense in the prior year period related to the introduction of our silver
dihydrogen citrate product to new partners. General and administrative expenses increased
by $359,870, to $571,184 in the quarter ended January 31, 2006, compared with the quarter
ended January 31, 2005. The increase in expense for the most recent quarter is primarily
due to the issuance of stock options for, and other expenses related to, investor
relations and investment consulting services. In addition and to a lesser extent,
insurance, legal and accounting fees increased year over year. Research and development
costs, including patent, license and product registration expenditures, declined by
$152,221 or 39.4% over the same period, primarily due to a reduction in patent related
legal fees. In the quarter ended January 31, 2006, research and development expense was
$234,500, and was primarily related to the continuing development of our silver dihydrogen
citrate technology.

Our net loss from operations,
excluding earnings from the Water Treatment Division prior to its sale, increased by
$147,300, from a net loss of $771,800 in the quarter ended January 31, 2005 to a net loss
of $919,200 in the quarter ended January 31, 2006. Earnings from the Water Treatment
Division in the quarter ended January 31, 2005, shown in the Statements of Operations as
Income from discontinued operations, were $241,000, resulting in a
consolidated net loss in the prior period of $530,800.

RESULTS OF OPERATIONS FOR THE SIX
MONTHS ENDED JANUARY 31, 2006 VERSUS SIX MONTHS ENDED JANUARY 31, 2005In the
financial statements included in this Report on Form 10Q-SB, the Water Treatment division,
which was sold in May 2005, is included as a Discontinued Operation in the Consolidated
Statements of Operations and Cash Flows presented for comparative purposes relating to the
periods ending January 31, 2005.

During the six months ended January
31, 2006, revenues of $114,600 increased by 50% over the six months ended January 31,
2005. Gross profit for the six months ended January 31, 2006 was $70,600 versus $54,600 in
the same period of the prior fiscal year. The gross margin percentage declined from 71% to
62% over the same period, primarily as we are now absorbing the overhead costs of our
manufacturing facility over a smaller number of products. In the prior fiscal year we
absorbed such costs over the products of the Water Treatment Division in addition to our
bioscience products.

Operating costs increased from
$1,452,100 in the six months ended January 31, 2005, to $1,591,900 in the six months ended
January 31, 2006. Included in these totals, selling expenses declined by $52,700, to
$241,700 in the current period compared with the same six months in the prior fiscal year,
primarily due to consulting expense in the prior year period related to the introduction
of our silver dihydrogen citrate product to new partners. General and administrative
expenses increased by $379,016, to $866,700 in the six months ended January 31, 2006,
compared with the six months ended January 31, 2005. The increase in expense is primarily
due to the issuance of stock options for, and other expenses related to, investor
relations and investment consulting services. In addition and to a lesser extent,
insurance, legal and accounting fees increased year over year. Research and development
costs, including patent, license and product registration expenditures, declined by
$186,509 or 27.8% over the same period, to $483,500 for the six months ended January 31,
2006, primarily due to a reduction in patent related legal fees.

Our net loss from operations,
excluding earnings from the Water Treatment Division prior to its sale, increased by
$123,800, from a net loss of $1,397,500 in the six months ended January 31, 2005 to a net
loss of $1,521,300 in the same period of the current fiscal year. Earnings from the Water
Treatment Division in the six months ended January 31, 2005, shown in the Statements of
Operations as Income from discontinued operations, were $391,200, resulting in
a consolidated net loss in the prior period of $1,013,600.

LIQUIDITY AND CAPITAL
RESOURCES
From inception through the present,
we have financed our operations primarily through our initial public offering in August of
1996, by subsequent private placement stock sales, and in May 2005 by the sale of our
Water Treatment Division.

In March 2005 we paid off a $300,000
convertible debenture and had $535,000 in loans forgiven in partial consideration for the
return of a trust deed. In addition, in May 2005 we paid off a $600,000 line of credit and
a $90,000 loan. As a result of these transactions, we currently have no long-term debt.

In May 2005, we sold the assets of
our Water Treatment Division to Maryland-based Innovative Medical Services, LLC (IMS LLC)
for $2,375,000. IMS LLC also assumed all liabilities associated with the Division. At
closing, we received $1,950,000 in cash and a promissory note in the amount of $425,000.
In June 2005, we received a cash payment of $225,000, leaving a $200,000 promissory note
(Notes receivable) on the Consolidated Balance Sheet as at July 31, 2005.
During the first quarter of the current fiscal year, we received the balance of $200,000
plus interest of $3,900 on the promissory note.

We agreed to continue to fund the
working capital of IMS LLC subsequent to the sale of the Water Treatment Division, until
such time as IMS LLC had in place their appropriate legal and tax registrations, in order
to enable the continuation of payroll and an uninterrupted supply of materials and
components for the business. At July 31, 2005, we had funded $132,521 of working capital
on IMS LLCs behalf, as shown in Other receivables on the balance sheet
as at July 31, 2005. During the first quarter of the current fiscal year, in addition to
the payment of the promissory note, IMS LLC reimbursed us for the working capital we had
provided subsequent to the sale. We are no longer providing any working capital for IMS
LLC.

As at January 31, 2006 we had current
assets of $268,300, a decrease of $670,800 from July 31, 2005. In addition to the
reduction in Notes receivable and Other receivables as discussed above, the decrease is
due primarily to cash used in our operations as outlined in the analysis later in this
section. At January 31, 2006 we had current liabilities of $374,200, an increase of
$20,900 from July 31, 2005, with a reduction in accounts payable partially offsetting an
$84,000 increase in accrued liabilities.

In the six months ended January 31,
2006, property, plant and equipment declined by $25,600 to $126,400, primarily due to
asset depreciation only being partially offset by capital investment. Other assets
increased by $451,200 over the six months through January 31, 2006, primarily due to the
recording of unvested options as a prepaid asset (Prepaid consulting) which
will be amortized over the life of associated consulting agreements. See Note 5 to the
financial statements included in this Report on Form 10Q-SB for further details of this
transaction. The $548,408 of prepaid consulting on the balance sheet as at January 31,
2006 was partially offset by an excess of patent amortization over patent capitalization
during the six months through January 31, 2006, and approximately $30,000 of capitalized
patents that were written off in the current fiscal year and which related to Water
Treatment Division technology that was not acquired by IMS LLC. The capitalized value of
patents and licenses at January 31, 2006, primarily related to our silver dihydrogen
citrate technology, was $2,116,100.

9

---



Net cash outflows were $333,300 for
the six months ended January 31, 2006. Excluding the receivables associated with the sale
of the Water Treatment Division as discussed above, net cash outflows were $665,800. Net
cash outflows for the same six months of the previous fiscal year were $276,400, excluding
cash generated from the operation of the Water Treatment Division as a discontinued
operation. Net operating cash outflows were $770,500 in the six months ended January 31,
2006 versus $812,400 in the same period in the prior fiscal year. While excluding the
receivables associated with the sale of the Water Treatment Division when comparing the
cash flows of the respective periods, the most significant factor in the increase in
operating cash outflows is the use of working capital; in the six months ended January 31,
2005, accounts payable and accrued liabilities grew by $111,100, whereas in the same
period of the current fiscal year they grew by $23,700. Additionally, cash flows related
to investment in research and development and in protecting our technology through
arbitration was greater in the current period than in the same period of the prior fiscal
year.

Net cash provided by financing
activities was $458,000 in the six months ended January 31, 2006, compared with $570,500
in the same period of the previous fiscal year. During the most recent six month period,
we borrowed and repaid $80,000 in short-term loans, whereas in the period ended January
31, 2005 we received $90,000 from such loans and carried the loan on the balance sheet at
the end of the period.

In the six months ended January 31,
2006, we received $458,000 from the proceeds of sales of common stock. In November 2005,
we received $30,000 from the sale of 39,999 shares of common stock in a private placement
to an accredited investor, for $0.75 per share. In the same month, an option was exercised
on 50,000 shares at an exercise price of $0.53 per share, resulting in proceeds to us of
$26,500, and in January 2006 an option was exercised on a further 50,000 shares at an
exercise price of $0.53 per share, also resulting in proceeds to us of $26,500. Also in
January 2006, we sold 500,000 shares of unregistered common stock for $375,000, or $0.75
per share, in a private placement to an unaffiliated, accredited investor.

With respect to all sales of our
common stock made during the periods presented herein, we relied on Section 4(2) of the
Securities Act of 1933, as amended. No advertising or general solicitation was employed in
offering the securities. The securities were offered solely to accredited or sophisticated
investors, who were provided all of the current public information available on PURE
Bioscience.

In the six months ended January 31,
2005, we received $480,500 from the proceeds of sales of common stock. Included in this
amount were a private placement which consisted of 125,000 shares of common stock at a
price of $.39 per share and a one-year option to purchase 12,500 shares of common stock at
$1.50 valued at $1,154, for a total of $50,000; the sale of 80,000 shares of common stock
for $40,000 ($0.50 per share); two private placements valued at $200,000 (366,667 shares
of common stock at an average price of $0.5455 per share); the receipt of $150,000 from
the exercise of 300,000 shares of common stock at $0.50 per share; a private placement of
60,000 shares of common stock at $0.49 per share and a one-year warrant to purchase 6,000
shares of common stock at $1.00 valued at $674, for a total of $30,000; and the receipt of
$10,500 from the exercise of an employee option.

At January 31, 2006 we had remaining
cash and cash equivalents of $72,600. Subsequent to the end of the quarter, we received
$450,000 from the sale of 500,000 shares of unregistered common stock to Michael Sitton, a
director of the Company, at $0.90 per share. We also we received $12,500 from the exercise
of 25,000 options. However, our existing working capital will not be sufficient to fund
our ongoing operations and our development plans. We are therefore currently seeking
additional sources of capital to fund operations and investment in planned expansion.
Future investments are expected to include development and expansion of our infrastructure
and manufacturing capacity, product launches, research and development projects and
regulatory submissions.

RISKS RELATED TO OUR
PLANS TO RAISE CAPITAL
We are currently seeking additional
capital, which will require us to issue securities such as our common stock. Issuance of
such securities will lead to the dilution of our existing shareholders. We may also
require further capital in future periods, which could include the issuance of debt or
equity, or convertible securities. The issuance of any such securities would, or could,
lead to the dilution of our existing shareholders. There is no guarantee that we will be
able to obtain capital on terms acceptable to us, or at all. Insufficient funds may
require us to delay, scale back or eliminate some or all of our research and product
development programs, license to third parties the right to commercialize products or
technologies that we would otherwise commercialize ourselves, or to reduce or cease
operations.

OTHER RISKS RELATED TO
OUR BUSINESSBy selling the Water Treatment
Division, we lost the most significant contributor to our historical revenue stream and
became less diversified. We are now a bioscience company focused on the marketing, selling
and continued development of our silver dihydrogen citrate antimicrobial technology and
our Triglycylboride pesticide technology. While the rewards in these fields are
potentially great, the risks, the regulatory hurdles and the costs of doing business are
also high.

Our silver dihydrogen citrate
technology is a platform, rather than a single use, technology. As such, products
developed from the platform fall under the jurisdiction of multiple U.S. and international
regulatory agencies. We currently have Environmental Protection Agency (EPA) registration
for our 2400-parts per million (ppm) technical grade SDC concentrate (trade name
Axenohl®) as well as for our Axen® and Axen®30 hard surface disinfectant
products for commercial, industrial and consumer applications including restaurants, homes
and medical facilities. We intend to fund and manage additional EPA regulated product
development internally and in conjunction with current regulatory consultants, however the
introduction of additional EPA regulated antimicrobial products could take several months.

Our technology also shows promise as
a broad-spectrum antimicrobial for use in human and veterinary healthcare products. We
have chosen to pursue development and product approvals through the U.S. Food and Drug
Administration (FDA) by partnering with Therapeutics, Incorporated, which has assumed
responsibility for the testing and regulatory process for selected potential FDA regulated
silver dihydrogen citrate-based products. We expect that Therapeutics experience
with drug development and FDA processing, especially with regard to dermal
pharmaceuticals, could lead to IND, NDA and/or 510-K filings for silver dihydrogen
citrate-based healthcare products with the FDA. The FDA and comparable agencies in many
foreign countries impose substantial limitations on the introduction of new products
through costly and time-consuming laboratory and clinical testing and other procedures.
The process of obtaining FDA and other required regulatory approvals is lengthy, expensive
and uncertain. There is no guarantee that either Therapeutics, Incorporated or ourselves
will be able to obtain the resources necessary to obtain such approvals, or that the
products will meet the strict criteria imposed by the FDA. It may be several years before
we are able to introduce any FDA regulated antimicrobial pharmaceutical products, if at
all.

10

---



If we are successful in bringing
additional EPA or FDA regulated products to market, there is no assurance that we will be
able to successfully manufacture or market the products or that potential customers will
buy them. For example, a current or future competitive product may have, or be perceived
as having, greater efficacy or cost effectiveness. In addition, the market in which we
will sell any such products is dominated by a number of large, well-capitalized
corporations, which may impact our ability to successfully market our products or maintain
any technological advantage we might develop. We may also be subject to changes in
regulations governing the manufacture and marketing of our products, which could increase
our costs, reduce any competitive advantage we may have, or adversely impact our marketing
effectiveness.

# 

VALUATION OF INTANGIBLE
ASSETS
SFAS 142 requires that goodwill and
other intangible assets be tested for impairment on an annual basis, and in certain
circumstances between annual tests. Recoverability of assets to be held for use is based
on expectations of future discounted cash flows from the related operations, and when
circumstances dictate, we adjust the asset to the extent the carrying value exceeds the
fair value of the asset. Our impairment review process is based on the discounted future
cash flow approach that uses our estimates of revenue driven by assumed market segment
share and estimated costs. Also included in our analysis is an estimate of revenues
expected from our agreement with Therapeutics, Incorporated. We have entered into an
agreement with Therapeutics Inc. for the development and commercialization of certain FDA
regulated silver dihydrogen citrate based products, where Therapeutics is responsible for
all development activities and regulatory filings. In the agreement, Therapeutics Inc. has
agreed to reimburse the Company for pre-contract acquisition and development costs of the
silver dihydrogen citrate intellectual property as well as reimbursement for ongoing
intellectual property costs associated with silver dihydrogen citrate. Following the
reimbursement of both Therapeutics and our costs, depending on the type of product
we will receive a minimum of 40% of all sales proceeds, licensing fees, royalty payments
and all other forms of cash and non-cash consideration received by the two parties. We
will also realize revenues from the sale of silver dihydrogen citrate raw material as an
active ingredient.

Judgments made by us related to the
expected useful lives of long-lived assets and our ability to realize discounted cash
flows in excess of the carrying amounts of such assets are affected by factors such as the
ongoing maintenance and improvements of the assets and changes in economic and market
conditions. As we assess the ongoing expected cash flows and carrying amounts of our
long-lived assets, these factors could cause us to realize a material impairment charge,
which would result in decreased results of operations and a decrease in the carrying value
of these assets on our consolidated balance sheet.

ITEM 3.   CONTROLS AND
PROCEDURESThe Company maintains disclosure
controls and procedures that are designed to ensure that information required to be
disclosed in the Companys Exchange Act reports is recorded, processed, summarized
and reported within the time periods specified in the SECs rules and forms, and that
such information is accumulated and communicated to the Companys management,
including its Chief Executive Officer and Chief Financial Officer, as appropriate, to
allow timely decisions regarding required disclosure based closely on the definition of
disclosure controls and procedures in Rule 13a-14(c). In designing and
evaluating the disclosure controls and procedures, management recognized that any controls
and procedures, no matter how well designed and operated, can provide only reasonable
assurance of achieving the desired control objectives, and management necessarily was
required to apply its judgment in evaluating the cost-benefit relationship of possible
controls and procedures.

As of the end of the previous fiscal
year, we carried out an evaluation under the supervision and with the participation of our
management, including the Companys Chief Executive Officer and the Companys
Chief Financial Officer, of the effectiveness of the design and operation of our
disclosure controls and procedures. Based on the foregoing, the Companys Chief
Executive Officer and Chief Financial Officer concluded that our disclosure controls and
procedures were effective.

There have been no significant
changes in our internal controls or in other factors that could significantly affect the
internal controls subsequent to the date the Company completed its evaluation.

PART II ITEM 1.   LEGAL PROCEEDINGSIn November 2004, we received a $14.2
million award resulting from a binding arbitration proceeding against NVID International,
Inc. through the American Arbitration Association International Centre for Dispute
Resolution. As a result, our royalty and other contractual obligations to NVID were
legally terminated. Our October 2003 arbitration action against NVID International and
Falken Industries, Ltd., sought damages and relief from continued and ongoing public
dissemination of false, misleading and disparaging statements. In March 2006, our November 2004
arbitration award against NVID was confirmed by the US District Court, Southern District of
California, as a federal judgment.

In October 2005, we received a
further $3.64 million award, including costs, resulting from the binding arbitration
proceeding against Falken Industries. The October 2005 arbitration award against Falken
Industries, Ltd. was confirmed by Judge M James Lorenz of the US District Court, Southern
District of California by an Order dated January 18, 2006. The Clerk of the Court entered
judgment in accordance with the award of the arbitrator on January 20, 2006. The judgment
was unopposed; however, Falken Industries, Ltd. subsequently filed a motion to set aside
the Courts Order and the resulting judgment. The matter has been briefed and is now
before the Court.

11

---



In June 2004, we filed an arbitration
action against Nickel Ltd. and Falken Industries Ltd., case number 50 T 133 00319 04, for
breach of contract regarding a license for Axen30. Nickel resisted arbitration, however on
September 30, 2005, the US District Court, Southern District of California ordered Nickel
to arbitration. The arbitration is in progress and currently set for hearing on the merits
in April 2006. Falken Industries was not part of the District Court matter to compel
arbitration, and has now refused to be a part of this arbitration procedure. On December
16, 2005, we filed a separate lawsuit against Falken Industries, Ltd. in the US District
Court, Southern District of California for breach of contract, injunctive relief, trade
libel, and declaratory relief regarding a license for Axen30 originally issued to Nickel,
Ltd. On December 22, 2005, Nickel, Ltd. filed for declaratory relief with the American
Arbitration Association International Centre for Dispute Resolution to clarify the
parties obligations under the Umbrella Agreement and the Axen30 License Agreement.

Nickel Ltd. has recently filed two
lawsuits under the jurisdiction of the Tribunal De Commerce De Paris. The first of these
actions was filed on October 26, 2005 against us under an agreement (the Super
Distribution Agreement) signed in January 2003, seeking an award in the amount of
approximately $14.6 million, including damages. The second lawsuit was filed on November
21, 2005 against Carline America, a Nevada corporation, and us, also under the Super
Distribution Agreement. Carline America was established by us solely for the Super
Distribution Agreement but never commenced operations or issued shares due to
Nickels breach of contract. This second lawsuit seeks an award in the amount of
approximately $21.9 million including damages from Carline, and also seeks to hold us
liable for the full amount. In January 2006, Emile Gouiran, Nickel, Ltd. and Falken
Industries, Ltd. filed a defamation lawsuit under the jurisdiction of the Tribunal De
Commerce De Paris against Michael L. Krall, Dennis Atchley, PURE Bioscience, PUREs
legal counsel, and other parties. We are currently, with our French counsel, evaluating
the three lawsuits; however, we believe each suit is frivolous, maliciously false, and
wholly without merit. These recent suits follow four previous suits brought by Nickel
against us in France, all of which were dismissed by the respective French courts.

ITEM 2.   CHANGES IN
SECURITIESIn November 2005, we sold 39,999
shares of unregistered common stock in a private placement to three accredited investors
for $0.75 per share. In December 2005, we issued 25,000 shares of common stock valued at
$19,250 in exchange for regulatory and consulting services. In January 2006, we sold
500,000 shares of unregistered common stock in a private placement to an unaffiliated,
accredited investor at $0.75 per share. During the three months ended January 31, 2006, we
also received $53,000 from the exercise of options on 100,000 shares.

In February, subsequent to the end of
the period presented herein, we sold 500,000 shares of unregistered common stock in a
private placement to Michael Sitton, a director of the Company, at $0.90 per share. Also
subsequent to the period ended January 31, 2006, there was a net exercise of an option on
15,000 shares of common stock that resulted in the issuance of 5,196 shares of common
stock; we received $12,500 from the exercise of an option on 25,000 shares; and we
received $10,000 from the exercise of a warrant to purchase 33,333 shares of unregistered
common stock.

With respect to sales made, we relied
on Section 4(2) of the Securities Act of 1933, as amended. No advertising or general
solicitation was employed in offering the securities. The securities were offered solely
to accredited or sophisticated investors who were provided all of the current public
information available on PURE Bioscience.

# ITEM 3.   DEFAULTS UPON
SENIOR SECURITIES

Not applicable.

# ITEM 4.   SUBMISSION OF MATTERS
TO A VOTE OF SECURITY HOLDERS

None.

# ITEM 5.   OTHER INFORMATION

Not applicable.

# ITEM 6.   EXHIBITS AND
REPORTS ON FORM 8-K

A.    
          The following Exhibits are filed as part of this report pursuant to Item 601 of
          Regulation S-B:

|3.1 (1) |  Articles of Incorporation, Articles of Amendment and Bylaws
|------- | -------------------------------------------------------------

|3.1.1(13) |  Articles
of Amendment dated March 11, 2002
|--------- | --------------------------------------------

|4.1 (1) |  Form of Class A Warrant
|------- | -------------------------

|4.2 (1) |  Form
of Class Z Warrant
|------- | -------------------------

|4.3 (1) |  Form
of Common Stock Certificate
|------- | ----------------------------------

|4.4 (1) |  Warrant
Agreement
|------- | -------------------

|4.5 (2) |  March
2000 Warrant
|------- | --------------------

|4.6 (3) |  January
2001 Warrant
|------- | ----------------------

|4.7 (4) | Convertible
Debenture
|------- | ----------------------

|4.8 (5) |  Convertible
Debenture Purchase Agreement
|------- | ------------------------------------------

|4.9 (6) | Convertible
Debenture Warrant
|------- | ------------------------------

|10.1 (1) | Employment
Contract/Michael L. Krall
|-------- | -------------------------------------

|10.2 (7) |   Manufacturing, Licensing and Distribution Agreement dated March 26, 2001
|-------- | ---------------------------------------------------------------------------

|10.3 (8) |  Axenohl License Agreement
|-------- | ---------------------------

|10.4 (9) |  Weaver  Roach X Assignment
|-------- | -----------------------------

|10.5 (9) |   Dodo  Agreement   [CONFIDENTIAL   TREATMENT  REQUESTED  FOR  CERTAIN  OMITTED
 INFORMATION  FILED                 SEPARATELY]
|-------- | --------------------------------------------------------------------------------------------------------------------------------

|10.6 (8) | Promissory Note of Michael Krall
|-------- | ---------------------------------

|10.7 (8) |  Promissory Note of Gary Brownell
|-------- | ----------------------------------

|10.8  (9) |  Nutripure Dealer Agreement
|--------- | ----------------------------

|10.9 (9) |  Sales Finance Agreement
|-------- | -------------------------

|10.10 (10) |  ETIH2O, Inc., Acquisition Agreement
|---------- | -------------------------------------

12

---



|10.11 (11) |  NVID Litigation Settlement Agreement
|---------- | --------------------------------------

|10.12 (12) |  Addendum #1 to NVID Settlement Agreement
|---------- | ------------------------------------------

|10.13(14) |    Therapeutics,  Incorporated  Agreement  [CONFIDENTIAL  TREATMENT  REQUESTED FOR
CERTAIN  OMITTED                 INFORMATION FILED SEPARATELY]
|--------- | --------------------------------------------------------------------------------------------------------------------------------------------------

|10.14 (15) |   Promissory Note dated November 2003 $4,750,000
|---------- | -------------------------------------------------

|10.15 (15) |   Promissory Note dated January 26, 2004 $100,000
|---------- | --------------------------------------------------

|13 (13) |  Subsidiaries of the Registrant
|------- | --------------------------------

|14.1 (16) |  Code of Ethics
|--------- | ----------------

|31.1 |  Section
302 Certification
|---- | ---------------------------

|31.2 |  Section
302 Certification
|---- | ---------------------------

|32.1 |  Section
906 Certification
|---- | ---------------------------

|32.2 |  Section
906 Certification
|---- | ---------------------------

|(1) | Incorporated
by reference from Form SB-2 registration statement SEC File
                    #333-00434 effective August 8, 1996
|--- | --------------------------------------------------------------------------------------------------------------------------------

|(2) | Incorporated
by reference from S-3 registration statement, SEC File #333-36248
                    effective on May 17, 2000
|--- | ----------------------------------------------------------------------------------------------------------------------------

|(3) | Incorporated
by reference from S-3 registration statement, SEC File #333-55758
                    effective on February 26, 2001
|--- | ---------------------------------------------------------------------------------------------------------------------------------

|(4) | Incorporated
by reference from S-3 registration statement, SEC File #333-61664
                    filed on May 25, 2001
|--- | ------------------------------------------------------------------------------------------------------------------------

|(5) | Incorporated
by reference from pre-effective amendment no. 1 to S-3 registration
                    statement, SEC File #333-61664 filed on July 10, 2001
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------------------

|(6) | Incorporated
by reference from pre-effective amendment no. 2 to S-3 registration
                    statement, SEC File #333-61664 filed on August 13, 2001
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------

|(7) | Incorporated
by reference from Current Report on Form 8-K filed on May 24, 2001                     as
amended on October 19, 2001
|--- | ----------------------------------------------------------------------------------------------------------------------------------

|(8) | Incorporated
by reference from the Amended Annual Report on Form 10KSB for the
                    fiscal year ended July 31, 2000 filed on October 19, 2001
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------

|(9) | Incorporated
by reference from Amended Form 10QSB for the nine month period                     ended
April 30, 2001 filed on October 19, 2001
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------

|(10) | Incorporated
by reference from the Amended Annual Report on Form 10KSB for the
                    fiscal year ended July 31, 2001 filed on November 13, 2001
|---- | -------------------------------------------------------------------------------------------------------------------------------------------------------------

|(11) | Incorporated
by reference from Current Report on Form 8-K filed on December 6,
                    2001
|---- | -------------------------------------------------------------------------------------------------------

|(12) | Incorporated
by reference from Amended Current Report on Form 8-K filed on
                    December 7, 2001
|---- | ---------------------------------------------------------------------------------------------------------------

|(13) | Incorporated
by reference from the Annual Report on Form 10KSB for the fiscal                     year
ended July 31, 2002 filed on October 29, 2003
|---- | ----------------------------------------------------------------------------------------------------------------------------------------------------

|(14) | Incorporated
by reference from the Amended Annual Report on Form 10KSB for the
                    fiscal year ended July 31, 2003 filed on January 30, 2004
|---- | ------------------------------------------------------------------------------------------------------------------------------------------------------------

|(15) | Incorporated
by reference from the Amended Quarterly Report for the three month
                    period ended October 31, 2003 filed on February 27, 2004
|---- | ------------------------------------------------------------------------------------------------------------------------------------------------------------

|(16) | Incorporated
by reference from the Annual Report on Form 10KSB for the fiscal                     year
ended July 31, 2004 filed on October 29, 2004
|---- | ----------------------------------------------------------------------------------------------------------------------------------------------------

# SIGNATURES

Pursuant to the requirement of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned thereunto duly authorized.

| | PURE Bioscience                                                                                                                                                                                          
| | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | By:   /s/ Michael L. Krall
          Michael L. Krall, President/CEO
          March 15, 2006
By:   /s/ Andrew J. Buckland
          Andrew J. Buckland, Chief Financial Officer
          March 15, 2006

13